Resultados da busca - P. Aftimos

  • Mostrando 1 - 2 resultados de 2
Refinar Resultados
  1. 1
    Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

    Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR tria... por Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana, Camilo Garcia, Patrick Emonts, Lieveke Ameye, Sigrid Stroobants, Manon Huizing, P. Aftimos, J. Tol, Wim J.G. Oyen, Daniëlle J. Vugts, Otto S. Hoekstra, Carolina P. Schröder, C. Willemien Menke‐van der Houven van Oordt, Thomas Guiot, Adrienne H. Brouwers, Ahmad Awada, Elisabeth G.E. de Vries, P. Flamen

    Publicado em 2015
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Sacituzumab govitecan in metastatic triple-negative breast cancer

    Sacituzumab govitecan in metastatic triple-negative breast cancer por A. Bardia, S.A. Hurvitz, S.M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S.D. Sardesai, K. Kalinsky, A.B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortés, J. O apos Shaughnessy, V. Diéras, C. Ferrario, P. Schmid, L.A. Carey, L. Gianni, M.J. Piccart, S. Loibl, D.M. Goldenberg, Q. Hong, M.S. Olivo, L.M. Itri, H.S. Rugo, ASCENT Clinical Trial Investigators

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: